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Abstract
Background: In definitive radiation therapy for head and neck cancer, clinically uninvolved cervical lymph nodes
are irradiated with a so-called ‘elective dose’ in order to achieve control of clinically occult metastases. As a
consequence of high-resolution diagnostic imaging, occult tumor volume has significantly decreased in the last
decades. Since the elective dose is dependent on occult tumor volume, the currently used elective dose may be
higher than necessary.
Because bilateral irradiation of the neck contributes to dysphagia, xerostomia and hypothyroidism in a dose
dependent way, dose de-escalation to these regions can open a window of opportunity to reduce toxicity and
improve quality of life after treatment.
Methods: UPGRADE-RT is a multicenter, phase III, single-blinded, randomized controlled trial.
Patients to be treated with definitive radiation therapy for a newly diagnosed stage T2-4 N0-2 M0 squamous cell
carcinoma of the oropharynx, hypopharynx or larynx are eligible. Exclusion criteria are recurrent disease, oncologic
surgery to the head and neck area, concomitant chemotherapy or epidermal growth factor receptor inhibitors.
In total, 300 patients will be randomized in a 2:1 ratio to a treatment arm with or without de-escalation of the
elective radiation dose and introduction of an intermediate dose-level for selected lymph nodes. Radiation therapy
planning FDG-PET/CT-scans will be acquired to guide risk assessment of borderline-sized cervical nodes that can be
treated with the intermediate dose level.
Treatment will be given with intensity-modulated radiation therapy or volumetric arc therapy with simultaneous-
integrated boost using an accelerated fractionation schedule, 33 fractions in 5 weeks. The primary endpoint is
‘normalcy of diet’ at 1 year after treatment (toxicity). The secondary endpoint is the actuarial rate of recurrence in
electively irradiated lymph nodes at 2 years after treatment (safety).
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Discussion: The objective of the UPGRADE-RT trial is to investigate whether de-escalation of elective radiation dose
and the introduction of an intermediate dose-level for borderline sized lymph nodes in the treatment of head and
neck cancer will result in less radiation sequelae and improved quality of life after treatment without compromising
the recurrence rate in the electively treated neck.
Trial registration: ClinicalTrials.gov Identifier: NCT02442375.
Keywords: Head and neck cancer, Squamous cell carcinoma, Accelerated radiation therapy, Dose reduction,
Dose de-escalation, Elective nodes, FDG-PET, Euality of life
Background
In definitive radiation therapy for head and neck cancer,
generally two dose-levels are delivered.
A high dose, the so-called “boost dose” to eradicate
macroscopic tumor and a lower dose, the so-called
“elective dose” to achieve control of clinically occult me-
tastases in cervical lymph nodes. The current equivalent
dose in 2 Gy fractions (EQD2) prescribed to the elective
volume is 45–50 Gy and is based on literature from the
nineteen-fifties [1]. At that time, assessment of the neck
only consisted of physical examination due to the lack of
sufficiently sensitive diagnostic imaging of lymph nodes.
Today, ultra-sound (US) with fine needle aspirated cy-
tology (FNAC), computed tomography (CT) and magnetic
resonance imaging (MRI) provide high resolution anatom-
ical detail and have a high sensitivity and specificity in the
detection of cervical lymph node metastases in head and
neck cancer [2], even in a neck without palpable lymph
nodes [3].
As a consequence of the implementation of high-
resolution diagnostic imaging techniques, tumor deposits
measuring only a few millimeters are now detected and
added to the boost volume. It is therefore plausible that
nowadays occult tumor volume in radiologically unin-
volved lymph nodes is much smaller than in the era before
the implementation of these imaging techniques. How-
ever, the radiation therapy dose prescription practice for
elective nodal regions has not changed over the years.
Since the dose required to control subclinical disease
is dependent on occult tumor volume [4, 5], it would
make sense to refine the traditional binary dose prescrip-
tion to a more gradual one that is proportional to tumor
volume. For this purpose, molecular imaging using fluor-
odeoxyglucose positron emission tomography (FDG-
PET) can improve the accuracy of current diagnostic im-
aging assuming that FDG-uptake represents tumor cell
density, or at least is a good surrogate for this [6].
The potential value of FDG-PET imaging in the man-
agement of cervical lymph nodes lies in the decision-
making process whether borderline-sized nodes should
be treated with a boost or elective dose [7]. It is even
conceivable that borderline-sized nodes having mild
FDG-uptake may not require the maximum dose since
they are likely to contain no or only a small tumor
volume. An intermediate dose level may be sufficient for
such nodes.
Because bilateral irradiation of cervical lymph node re-
gions contributes to dysphagia, xerostomia and thyroid dys-
function in a dose dependent way [8, 9], dose reduction to
these regions can open a window of opportunity to reduce
toxicity and improve quality of life after treatment [10].
A treatment planning study performed at the Radbou-
dumc showed that de-escalation of the elective dose as
proposed in this study protocol, can reduce the dose to
normal tissues such as the swallowing musculature,
thyroid- and salivary glands (unpublished data). Normal
tissue complication probability models from the available
literature [11–15] showed that a relevant decrease in
toxicity can be expected for xerostomia (absolute up to
14%, relative risk up to 39%), dysphagia (absolute up to
12%, relative risk up to 67%) and hypothyroidism (abso-
lute up to 20%, relative risk up to 50%).
Given these considerations we believe that the traditional
binary dose prescription in head and neck cancer is out-
dated. In this trial, a more gradual dose prescription will be
used with de-escalation of the elective radiation dose and
the introduction of an intermediate dose-level in the treat-
ment of head and neck cancer. The aim is to investigate
whether such a treatment will result in less radiation seque-
lae and improved quality of life after treatment (expressed
as a normalcy of diet) without compromising the recur-
rence rate in electively irradiated lymph nodes.
Methods/Design
Objectives
To determine whether a more gradual dose prescription
with de-escalation of the elective radiation dose and the
introduction of an intermediate dose-level in the treat-
ment of head and neck cancer will result in less radiation
sequelae and improved quality of life after treatment
(toxicity) without compromising the recurrence rate in
electively irradiated lymph nodes (safety).
Study design
This is a multicenter, phase III, single-blinded, random-
ized controlled trial.
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Treatment allocation at randomization will be at a ratio
of 2:1 in favor of the intervention arm. Randomization will
be balanced for institution, tumor-site, T- and N-stage,
and human papillomavirus status using minimization with
a random element. Randomization and clinical trial data
management is provided by the IKNL clinical research
department.
A flow chart giving an overview of the study design is
shown in Fig. 1.
In- and exclusion criteria
Adult patients having a new, pathologically proven squa-
mous cell carcinoma located in the larynx, oropharynx
or hypopharynx with stage T2-4 N0-2 M0 are eligible for
inclusion after written informed consent. Patients must
be able to undergo accelerated radiation therapy and
have a World Health Organization performance status
of 0–2.
Main exclusion criteria are concomitant chemotherapy
or epidermal growth factor receptor inhibitors for this
tumor, prior anticancer treatment to the head and neck
area (surgery, chemotherapy or radiation therapy), previ-
ous malignancies or uncontrolled diabetes mellitus.
Endpoints
Primary endpoint (toxicity): ‘normalcy of diet’ at 1 year after
treatment, measured using the performance status scale for
patients with head and neck cancer (PSS-HN) [16].
Secondary endpoint (safety): actuarial rate of recur-
rence in electively irradiated lymph nodes at 2 years after
treatment.
Other endpoints:
Acute toxicity (mucositis, dysphagia and skin reaction).
Late toxicity (with focus on xerostomia, dysphagia and
hypothyroidism).
Quality of life (general-, xerostomia- and dysphagia
related quality of life).
Recurrence (local, regional, loco-regional and distant).
Survival (overall, disease specific and disease free).
Sample size calculation
This study was designed to detect a 10-point difference on
the PSS-HN ‘normalcy of diet’ score at 12 months after ra-
diation therapy with a power of 90% at a two-sided signifi-
cance level of 0.05. An average ‘normalcy of diet’ score of
70 is expected after standard treatment. To achieve this
significance level with an unequal randomization ratio
(2:1), a total of 300 patients needs to be included.
The current rate of recurrence in electively irradiated
lymph nodes was estimated to be 5% at 2 years after
treatment [17]. An equal rate of recurrence is expected
in the intervention arm, despite elective dose de-
escalation. A recurrence rate of ≥10% will be considered
clinically relevant and unacceptable. This difference can
be detected with the number of patients planned for the
primary outcome of the study and a one-sided α = 0.10.
The total duration of this trial is estimated to be
6 years (4 years accrual, 2 years follow-up).
Pre-treatment evaluation
Pre-treatment evaluation will include physical examin-
ation and flexible endoscopy of the upper aerodigestive
tract, biopsy of the tumor, MRI and/or CT-scan of the
head and neck area, and US of the neck including FNAC
of cervical lymph nodes. All patients are evaluated by a
multidisciplinary head-and-neck oncology team.
Radiation therapy planning FDG-PET/CT-scan
In order to ensure that in the multicenter setting of this
trial, the acquired quantitative data and standardized uptake
Fig. 1 Flow chart giving an overview of the study design. *the reported dose is the equivalent dose in 2 Gy fractions (EQD2)
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value (SUV) recoveries are interchangeable between study
sites, all FDG-PET/CT-scans will be acquired on EARL
accredited scanners (http://earl.eanm.org) following the
European Association of Nuclear Medicine (EANM) pro-
cedure guidelines for tumor PET imaging v2.0 [18].
FDG-PET/CT-scans of the head and neck area will be
acquired in radiation therapy treatment position using a
custom-made thermoplastic head, neck and shoulders
mask to immobilize the patient during radiation therapy
and the scanning procedures. A diagnostic CT-scan using
an intravenous contrast agent will be acquired in one ses-
sion on the PET/CT-scanner for treatment planning.
Standardized uptake ratio (SUR)
In this trial, the SUV will be normalized by an internal
image-derived standard, in order to minimize inter-study
variability of FDG-uptake [18]. The cervical spinal cord
will be used as the internal image-derived standard [19].
The SUR will be calculated using the following
formula:
SURmax = (SUVmaxin region of interest/SUVmeanof in-
ternal standard ).
Risk assessment of lymph nodes
Intervention arm
In the intervention arm, lymph nodes will be classified
into three risk-levels and will be treated with a corre-
sponding radiation dose. The FDG-PET-scan will guide
risk assessment using standardized methods in order to
minimize inter-institutional and inter-operator variations.
 High-risk (macroscopic tumor): comprises metastatic
nodes that will be identified by (1) positive cytology
or (2) necrosis on imaging or (3) SURmax ≥ 2.0.
 Intermediate-risk: comprises lymph nodes of
borderline size having intermediate FDG-uptake and
will be identified by (1) summed long- and
short-axis diameter ≥ 17 mm and (2) SURmax ≥ 1.5
and <2.0 and (3) cannot be high-risk (e.g. positive
cytology or necrosis on imaging). These criteria are
based on an in-depth risk assessment on recurrence
in 1166 electively irradiated nodes in 264 patients.
Not overtly pathologic lymph nodes with a summed
diameter ≥ 17 mm had an increased risk to recur
after elective treatment (Hazard Ratio: 17.8, 95%CI:
5.7–55, p < 0.001) [17].
 Low-risk (microscopic tumor): comprises elective
lymph node regions defined in the protocol based
on tumor site and stage and will be delineated
according to published guidelines [20].
Retropharyngeal lymph nodes will be evaluated by
traditional means as standardized FDG-PET-guided risk-
assessment is not applicable to these nodes.
Control arm
In the control arm, no areas of intermediate risk will be
identified. Lymph nodes are either assigned to the high-
risk (macroscopic) volume or low-risk (elective) volume
by traditional means (positive cytology or necrosis on
imaging or short-axis diameter ≥ 10 mm, ≥11 mm for
subdigastric nodes).
The FDG-PET-scan may be used in the decision mak-
ing process by means of visual interpretation.
Delineation and margins
For the primary tumor, the gross target volume (GTVp)
will be delineated by traditional means using information
from clinical examination and diagnostic imaging (CT
and/or MRI) and will encompass all overtly macroscopic
disease. In both treatment arms, a biological target vol-
ume (BTVp) of the primary tumor is created by means
of adaptive threshold iso-contouring based on the FDG-
SUR maps [19]. Gross / high-risk lymph node metasta-
ses will be delineated separately (GTVn).
A clinical target volume (CTV) is created to cover all
routes of potential subclinical disease spread.
The GTVp will be expanded by a 3D margin of 10 mm
and the GTVn will be expanded by a 3D margin of
5 mm (10 mm in case of extra nodal disease on imaging)
in order to create the CTVhigh-risk. The CTVhigh-risk will
be adjusted for anatomical borders in which microscopic
disease is unlikely to extend. No CTV expansion will be
used for intermediate-risk lymph nodes as extra nodal
disease is unlikely in these nodes.
To take patient set-up uncertainties into account, a plan-
ning target volume (PTV) will be created by extension of the
CTV with a 3D margin of 3-5 mm (according to the partici-
pating centers protocols). Additionally, for the high-risk
tumor volume an additional PTVBGTV-high-risk will be created
by extension of the BTVp and GTVn with a 3D margin of 3-
5 mm. Differences in target volumes and dose prescription
between the treatment arms are illustrated in Fig. 2.
Organs at risk will be delineated according to pub-
lished international consensus guidelines [21]. Standard-
ized naming of target volumes and organs at risk will
facilitate inter-institutional data analysis in this multi-
center trial [22].
Radiation therapy regimen
Patients will be treated with accelerated external beam
radiation therapy (EBRT) using volumetric modulated
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arc therapy (VMAT) or intensity modulated radiation
therapy (IMRT) with simultaneous integrated boost
(SIB) techniques to deliver multiple dose levels. The
total treatment consists of 33 fractions in an overall
treatment time of 33 days (5 weeks). During the first
4 weeks of treatment, 6 fractions will be delivered in 5
consecutive days per week. In the last week of treatment,
9 fractions will be delivered (i.e. 4 days bid treatment).
The interval between fractions will be at least 6 h.
According to the participating centers protocols, offline
or online cone beam CT-scans will be made during
treatment to verify correct positioning of the patient
during irradiation.
Dose prescriptions for the treatment arms are shown
in Table 1.
Follow-up
Acute toxicity will be evaluated weekly during treatment
and every 2 weeks thereafter, until acute toxicity is com-
pletely healed. Acute toxicity will be scored using the
common toxicity criteria v2.0 [23]. Standard oncologic
follow-up visits are scheduled every 2 months during the
1st year and every 3 months during the 2nd year, after
which study participation ends. However, oncologic
follow-up will continue every 4 months during the 3rd
year and twice annually until at least 5 years of follow-
up. During oncologic follow-up visits, late toxicity, re-
currence and survival will be evaluated. Late toxicity will
be scored using the RTOG/EORTC late radiation mor-
bidity scoring criteria [24].
Periodical study visits will be scheduled once before
treatment and at 3, 6, 12 and 24 months after radiation
therapy. Subjects will undergo assessment of the swal-
lowing function, thyroid- and salivary glands function
and quality of life questionnaires will be completed.














Fig. 2 Radiation therapy planning FDG-PET/CT-scan of a patient with
an laryngeal squamous cell carcinoma (red arrow) with an intermediate
risk lymph node in level 3 right (red arrow) (a + b). Comparison of dose
planning conform this study protocol for the control-arm (c) and
intervention-arm (d) shows the potential of FDG-PET guided gradient
dose prescription with dose reduction to the elective neck in order to
better spare organs at risk
Table 1 Dose prescription
Target volume Dose (fraction dose) (Gy) aEQD2 (Gy)
Intervention-arm Control-arm
PTVGBTV-high-risk 66 (2.00) 66 (2.00) ≈ 73
PTVCTV-high-risk 62 (1.88) 62 (1.88) ≈ 67
PTVintermediate-risk 58 (1.76) - ≈ 60
PTVlow-risk 42 (1.27) 48 (1.45) ≈ 35 vs. 45
aThe equivalent dose in 2 Gy fractions (EQD2) was calculated using the linear-
quadratic model using an α/β = 10 Gy for tumor [34]. Differences in treatment
time were taken into account by a correction of 0.6 Gy per day to compensate
for tumor repopulation [35]
An accelerated fractionation schedule will be used, 33 fractions in 5 weeks
(33 days)
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Planning FDG-PET/CT-scan x
Acute toxicity (CTC v2.0) x x x
Late toxicity (RTOG-EORTC) x x x x
Assessment of thyroid function
(Blood analysis)
x x x x
Dysphagia related quality of life
(PSS-HN, SWAL-QOL)












x x x x
General quality of life
(EORTC QLQ-C30,
EORTC H&N35)
x x x x x
Assessment of recurrence each follow-up
visit
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Assessment of recurrence
If recurrence is suspected during follow-up, additional
imaging by MRI, CT, PET or US with FNAC will be
performed whatever is judged necessary by the attending
physician. Examination under general anesthesia is
performed if deemed necessary. All recurrences must be
confirmed by cytology or histology.
Central evaluation will be done for all regional recur-
rences in order to determine if the recurrence occurred in
an electively irradiated lymph node. The exact site of recur-
rence will be reconstructed by performing co-registration
of the planning CT-scan with diagnostic imaging of the
recurrence.
All recurrences in electively irradiated lymph nodes
will be reported as a serious adverse event since this is
the safety endpoint of this trial.
Functional assessments
 Salivary gland function will be evaluated in a part of
the participating centers only. Stimulated parotid
and submandibular salivary flow rates (sialometry)
will be measured using techniques described
previously [25, 26]. Samples of saliva collected with
sialometry will be analyzed for its composition
(sialochemistry).
 Swallowing function will be evaluated using the
water swallowing test [27]. Additional functional
performance will be evaluated by the Performance
Status Scale for Head & Neck Cancer Patients
(PSSH-HN) [16].
 Thyroid gland function will be evaluated using
standard blood analysis measuring the thyroid
stimulating hormone and free thyroxin.
Assessment of quality of life
For evaluation of general quality of life, the EORTC QLQ-
C30 and EORTC QLQ-H&N35 questionnaires will be used
[28, 29]. Xerostomia related quality of life will be evaluated
using the Groningen Radiation Therapy Induced Xerosto-
mia questionnaire (GRIX) [30] and dysphagia related
quality of life will be evaluated using the Swallowing
Quality of Life Questionnaire (SWAL-QOL) [31].
Statistical analysis
All analyses concerning treatment effects will be done
according to the intention to treat principle. The student’s
t-test will be used to compare ‘normalcy of diet’ scores at
1 year after treatment, the primary endpoint of this trial.
A Kaplan-Meier estimate will be calculated for the actuar-
ial rate of recurrence in electively irradiated lymph nodes
at 2 years after treatment. Actuarial rates on recurrence
and survival will be determined by the date of histopatho-
logical diagnosis. Differences between the treatment arms
will be assessed using the log-rank test.
For each quality of life questionnaire, data will be in-
cluded in the analysis if a patient filled in the question-
naire at least at start and at one time-point during the
study. Differences in quality of life over time between
the intervention- and control arm will be analyzed by
using a linear mixed model for repeated measurements.
Difference in quality of life scores ≥10 points will be
considered clinically relevant [32].
Safety assurance
After every 5 recurrences in electively irradiated lymph
nodes, an interim analysis will be performed following
the ‘group sequential approach’ comparing the recur-
rence rate in the two treatment arms [33]. The p-value
for the log-rank test statistic will be compared to a nom-
inal α of 0.042 at each interim analysis (i.e. critical value
of 1.728) to ensure an overall one-sided α of 0.10 [33].
For this calculation, it is assumed that accrual of 300 pa-
tients takes 4 years and that the vast majority of recur-
rences will be detected within 24 months.
A safety committee will be installed to undertake in-
terim review of the trial safety. The safety committee will
consist of an independent statistician and two experienced
radiation oncologists in the field of head and neck cancer
and will recommend on (dis)continuation of the trial.
Quality assurance
In order to ensure quality and uniformity between centers,
delineation, segmentation and treatment planning guide-
lines are described in detail in the protocol. The study
protocol was discussed with the participating centers until
consensus was reached.
Prior to opening inclusion, all participating centers will
perform a dummy run in order to assess compliance with
the protocols. Also during inclusion, quality assurance by
central review will occur prospectively for the first 3 pa-
tients included at each participating center, and will occur
retrospectively for all included patients thereafter.
Discussion
Current status
A total of 6 head and neck centers (or affiliated) will
participate and include: the Radboudumc Nijmegen,
University Medical Center Utrecht, VU University Med-
ical Center Amsterdam, MAASTRO clinic Maastricht,
Radiotherapiegroep Arnhem and Radiotherapeutisch
Instituut Friesland.
The first patient was included in august 2016 and ac-
crual is expected to continue for 4 years.
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